186 related articles for article (PubMed ID: 3141592)
1. Ifosfamide and mesna: marginally active in patients with advanced carcinoma of the pancreas.
Ajani JA; Abbruzzese JL; Goudeau P; Faintuch JS; Yeomans AC; Boman BM; Nicaise C; Levin B
J Clin Oncol; 1988 Nov; 6(11):1703-7. PubMed ID: 3141592
[TBL] [Abstract][Full Text] [Related]
2. Phase II experience with ifosfamide/mesna in gynecologic malignancies: preliminary report of Gynecologic Oncology Group studies.
Sutton GP; Blessing JA; Photopulos G; Berman ML; Homesley HD
Semin Oncol; 1989 Feb; 16(1 Suppl 3):68-72. PubMed ID: 2539647
[TBL] [Abstract][Full Text] [Related]
3. Phase II trial of ifosfamide and mesna in advanced ovarian carcinoma: a Gynecologic Oncology Group Study.
Sutton GP; Blessing JA; Homesley HD; Berman ML; Malfetano J
J Clin Oncol; 1989 Nov; 7(11):1672-6. PubMed ID: 2509641
[TBL] [Abstract][Full Text] [Related]
4. Phase II trial of ifosfamide and mesna in previously treated patients with non-Hodgkin's lymphoma: Cancer and Leukemia Group B Study 8552.
Case DC; Anderson J; Ervin TJ; Gottlieb A
Med Pediatr Oncol; 1988; 16(3):182-6. PubMed ID: 3132591
[TBL] [Abstract][Full Text] [Related]
5. Phase II study of ifosfamide and mesna in nonsquamous carcinoma of the cervix: a Gynecologic Oncology Group study.
Sutton GP; Blessing JA; DiSaia PJ; McGuire WP
Gynecol Oncol; 1993 Apr; 49(1):48-50. PubMed ID: 8482560
[TBL] [Abstract][Full Text] [Related]
6. High-dose alkylation therapy using ifosfamide infusion with mesna in the treatment of adult advanced soft-tissue sarcoma.
Stuart-Harris RC; Harper PG; Parsons CA; Kaye SB; Mooney CA; Gowing NF; Wiltshaw E
Cancer Chemother Pharmacol; 1983; 11(2):69-72. PubMed ID: 6414732
[TBL] [Abstract][Full Text] [Related]
7. A phase II Gynecologic Oncology Group trial of ifosfamide and mesna in advanced or recurrent adenocarcinoma of the endometrium.
Sutton GP; Blessing JA; DeMars LR; Moore D; Burke TW; Grendys EC
Gynecol Oncol; 1996 Oct; 63(1):25-7. PubMed ID: 8898163
[TBL] [Abstract][Full Text] [Related]
8. Phase II trial of ifosfamide and mesna in patients with advanced or recurrent squamous carcinoma of the cervix who had never received chemotherapy: a Gynecologic Oncology Group study.
Sutton GP; Blessing JA; McGuire WP; Patton T; Look KY
Am J Obstet Gynecol; 1993 Mar; 168(3 Pt 1):805-7. PubMed ID: 8456884
[TBL] [Abstract][Full Text] [Related]
9. Treatment of metastatic renal cancer with ifosfamide and mesnum with and without irradiation.
Fosså SD; Talle K
Cancer Treat Rep; 1980; 64(10-11):1103-8. PubMed ID: 6780190
[TBL] [Abstract][Full Text] [Related]
10. The efficacy of mesna (2-mercaptoethane sodium sulfonate) as a uroprotectant in patients with hemorrhagic cystitis receiving further oxazaphosphorine chemotherapy.
Andriole GL; Sandlund JT; Miser JS; Arasi V; Linehan M; Magrath IT
J Clin Oncol; 1987 May; 5(5):799-803. PubMed ID: 3106585
[TBL] [Abstract][Full Text] [Related]
11. Treatment of ifosfamide-induced urothelial toxicity by oral administration of sodium 2-mercaptoethane sulphonate (MESNA) to patients with inoperable lung cancer.
Araujo CE; Tessler J
Eur J Cancer Clin Oncol; 1983 Feb; 19(2):195-201. PubMed ID: 6402369
[TBL] [Abstract][Full Text] [Related]
12. Early phase II Gynecologic Oncology Group experience with ifosfamide/mesna in gynecologic malignancies.
Sutton GP; Blessing JA; Photopulos G; Berman ML; Homesley HD
Cancer Chemother Pharmacol; 1990; 26 Suppl():S55-8. PubMed ID: 2112054
[TBL] [Abstract][Full Text] [Related]
13. High-dose ifosfamide with mesna uroprotection: a phase I study.
Elias AD; Eder JP; Shea T; Begg CB; Frei E; Antman KH
J Clin Oncol; 1990 Jan; 8(1):170-8. PubMed ID: 2104923
[TBL] [Abstract][Full Text] [Related]
14. Phase II trial of ifosfamide and mesna in leiomyosarcoma of the uterus: a Gynecologic Oncology Group study.
Sutton GP; Blessing JA; Barrett RJ; McGehee R
Am J Obstet Gynecol; 1992 Feb; 166(2):556-9. PubMed ID: 1536229
[TBL] [Abstract][Full Text] [Related]
15. Continuous 5-day infusion of ifosfamide with mesna in inoperable pancreatic cancer patients: a phase II study.
Cerny T; Martinelli G; Goldhirsch A; Terrier F; Joss R; Fey MF; Brunner KW; Küpfer A
J Cancer Res Clin Oncol; 1991; 117 Suppl 4():S135-8. PubMed ID: 1795002
[TBL] [Abstract][Full Text] [Related]
16. Response to ifosfamide and mesna: 124 previously treated patients with metastatic or unresectable sarcoma.
Antman KH; Ryan L; Elias A; Sherman D; Grier HE
J Clin Oncol; 1989 Jan; 7(1):126-31. PubMed ID: 2491883
[TBL] [Abstract][Full Text] [Related]
17. Phase II study of ifosfamide and mesna in patients with metastatic breast cancer.
Walters RS; Holmes FA; Valero V; Esparza-Guerra L; Hortobagyi GN
Am J Clin Oncol; 1998 Aug; 21(4):413-5. PubMed ID: 9708645
[TBL] [Abstract][Full Text] [Related]
18. Phase II trial of ifosfamide and mesna in previously treated patients with non-Hodgkin's lymphoma: Cancer and Leukemia Group B study 8552.
Case DC; Anderson J; Ervin TJ; Gottlieb A
Hematol Oncol; 1991; 9(4-5):189-96. PubMed ID: 1743622
[TBL] [Abstract][Full Text] [Related]
19. Ifosfamide with mesna uroprotection in the management of lung cancer.
Holoye PY; Glisson BS; Lee JS; Dhingra HM; Murphy WK; Umsawasdi T; Levy JK; Jeffries D; Raber MN; Hong WK
Am J Clin Oncol; 1990 Apr; 13(2):148-55. PubMed ID: 2156418
[TBL] [Abstract][Full Text] [Related]
20. High-dose ifosfamide with mesna and granulocyte-colony-stimulating factor (recombinant human G-CSF) in patients with unresectable malignant mesothelioma.
Talbot SM; Rankin C; Taub RN; Balcerzak SP; Bhoopalam N; Chapman RA; Baker LH; Middleman EL; Antman KH
Cancer; 2003 Jul; 98(2):331-6. PubMed ID: 12872353
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]